DEF 14A: NeueHealth Seeks Stockholder Approval for Amended Incentive Plan and Director Elections at 2024 Annual Meeting

NeueHealth, Inc. is holding its 2024 Annual Meeting of Stockholders virtually on May 2, 2024, to vote on key proposals including the election of directors and approval of an amended omnibus incentive plan.

Summary

• NeueHealth, Inc. is inviting stockholders to its 2024 Annual Meeting to be held virtually on May 2, 2024.
• Stockholders will vote on the election of ten directors, ratification of Deloitte & Touche LLP as the independent accounting firm, approval of executive compensation, and approval of the Second Amended and Restated 2021 Omnibus Incentive Plan.
• The Board recommends voting 'FOR' all proposals.
• The meeting will be held virtually, and stockholders of record as of March 22, 2024, are entitled to vote.
• The company has shifted its focus to value-driven healthcare through owned and affiliated clinics and enabling independent providers to thrive in performance-based arrangements.

Sentiment

Score: 7

Explanation: The document presents a balanced view of the company's strategic direction and governance matters. While there are challenges related to stock price and equity compensation, the overall tone is positive and forward-looking.

Positives

• The company is committed to aligning the interests of payors, providers, and consumers to deliver a better healthcare experience.
• The company is confident in the future of its differentiated, value-driven care model focused on NeueCare and NeueSolutions.
• The company is taking steps to reduce the size of the Board from 12 to 10 members to align with the company's updated strategy.
• The Amended Plan continues what the company believes are good corporate governance practices from the 2021 Omnibus Incentive Plan.
• The company is focused on increasing the proportion of pay that is denominated in equity in order to strengthen the alignment of management rewards with the long-term returns delivered to stockholders.

Negatives

• The substantial decrease in the company's stock price since its IPO (by approximately 99% through March 15, 2024) has significantly impacted the number of shares available for issuance under the Existing Plan.
• The company was unable to grant all of its planned 2024 annual equity-based compensation awards due to the small number of shares available.
• The company reduced the planned size of its 2024 annual equity-based award by approximately 40% and postponed the grant to the date of the Annual Meeting, with such grant being contingent on receiving stockholder approval of the Amended Plan.

Risks

• If the Amended Plan is not approved by stockholders, the company would likely be compelled to alter its compensation program to increase the cash-based component of such program, which would decrease the amount of free cash flow available for other purposes.
• The company's success is dependent on its ability to use market relevant compensation to attract, retain and motivate the most talented professionals.
• The healthcare industry continues to evolve and shift towards value-based care, which may present challenges and uncertainties for the company.

Future Outlook

The company is confident in the future of its differentiated, value-driven care model focused on its two go-forward business segments, NeueCare and NeueSolutions.

Management Comments

• At our core, we are a value-driven healthcare company grounded in the belief that all health consumers are entitled to high-quality, coordinated healthcare.
• We believe that we can significantly reduce the current friction and lack of coordination in today's healthcare system by aligning the interests of payors and providers to enable a seamless, consumer-centric healthcare experience that drives value for all.
• Since our founding, we have been committed to uniquely aligning the interests of payors, providers, and consumers to deliver a better healthcare experience for all.

Industry Context

The healthcare industry continues to evolve and shift towards value-based care, which is driving NeueHealth's strategic focus and business model.

Corporate Governance

Related Party Transactions

• The company is party to a registration rights agreement with certain stockholders including New Enterprise Associates, Bessemer Venture Partners, StepStone, Town Hall Ventures, and certain subsidiaries of Cigna.
• On August 4, 2023, the company entered into a Credit Agreement with NEA 18 Venture Growth Equity, L.P. and the lenders from time to time party thereto, to provide for a credit facility pursuant to which, among other things, the lenders have provided $60.0 million delayed draw term loan commitments.
• On October 2, 2023, the company entered into Incremental Amendment No. 1 to the New Credit Agreement with California State Teachers Retirement System (CalSTRS), which provided for a term loan commitment increase to the New Credit Agreement in an aggregate principal amount of $6.4 million.

Stakeholder Impact

• Approval of the Amended Plan is intended to benefit employees by providing market-competitive equity compensation.
• The election of directors will impact the leadership and oversight of the company.
• The advisory vote on executive compensation allows stockholders to express their views on the company's pay practices.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its 2024 Annual Meeting of Stockholders on May 2, 2024.
• The company will file a Registration Statement on Form S-8 with the SEC with respect to the additional shares of the Company's common stock authorized for issuance pursuant to the Amended Plan as soon as reasonably practicable following stockholder approval.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Director Election, Executive Compensation, Incentive Plan, NeueHealth, Stockholders, Governance